ArticleThe American journal of tropical medicine and hygiene2025
Detection of the Tigecycline Resistance-Mediating tet(Y) Gene in Acinetobacter baumannii Isolates from Intensive Care Unit Patients in Pakistan.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii (A. baumannii) is a Gram-negative, nonfermenting bacterium implicated as a major cause of opportunistic infections in healthcare settings because it is a multidrug-resistant organism. Tigecycline was developed to circumvent the prevalent mechanism of A. baumannii resistance against tetracycline. This study aims to determine the frequency of tigecycline resistance and to characterize the tigecycline-resistant tet(Y), tet(X), and tet(A) genes in A. baumannii clinical isolates. A descriptive cross-sectional study was conducted at Lahore General Hospital (LGH), Lahore, Pakistan, from February 2023 to February 2024. A total of 195 A. baumannii samples were isolated from various samples collected from patients admitted to the intensive care unit of LGH over a period of 1 year. The antimicrobial susceptibility of A. baumannii was assessed using the Kirby-Bauer disc diffusion assay, and the results were reported according to the Clinical and Laboratory Standards Institute 2022 guidelines. The activity of tigecycline was reported according to the British Society for Antimicrobial Chemotherapy 2021 guidelines. The detection of tigecycline resistance genes tet(Y), tet(X), and tet(A) was performed using polymerase chain reaction, and the amplified products were confirmed using Sanger sequencing. Acinetobacter baumannii were resistant to multiple antibiotics. Minocycline was the most effective antibiotic, with 10.8% resistance, whereas cefotaxime was the least effective, with 74.4% resistance in 195 isolates of A. baumannii. Resistance to tigecycline was detected in 9% of isolates of A. baumannii. The tet(A) gene was the most frequently found gene, present in 20% of the tigecycline-resistant isolates, followed by tet(X) and tet(Y) genes in 18% and 9% of isolates, respectively. A high frequency of plasmid-mediated tigecycline resistance was detected in A. baumannii samples, with a high prevalence of tet(Y), tet(X), and tet(A) genes. This emphasizes the need for antibiotic stewardship, the detection of resistance profiles, and understanding underlying molecular mechanisms to plan clinical management effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.